CompletedNCT05402111

A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard

Medication studyAges 18–65United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations: Little Rock and 6 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateStarted: June 13, 2022

Recruitment status: Completed
Enrollment listed in the registry: 31
Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT05402111
Official title: Show the full official title
A Randomized, Open-Label, Single Dose, Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects With Schizophrenia

Completed

Little Rock · Rogers · Long Beach

4 more locations

FAQ

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SEP-363856 and Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole).

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.